Skip to main content
PMC home page
Frontiers in Neuroscience logoLink to Frontiers in Neuroscience
. 2021 Mar 3;15:633576. doi: 10.3389/fnins.2021.633576

The Associations of Cerebrospinal Fluid ApoE and Biomarkers of Alzheimer’s Disease: Exploring Interactions With Sex

Ying Liu 1,†, Jing-Hui Song 1,†, Wei Xu 2, Xiao-He Hou 2, Jie-Qiong Li 1, Jin-Tai Yu 3,*, Lan Tan 2,*, Song Chi 1,*; and Alzheimer’s Disease Neuroimaging Initiative‡
PMCID: PMC7968417  PMID: 33746700

Abstract

Background

Sex-related difference in Alzheimer’s disease (AD) has been proposed, and apolipoprotein E (ApoE) isoforms have been suggested to be involved in the pathogenesis of AD.

Objective

We aimed to explore whether cerebrospinal fluid (CSF) ApoE is associated with AD biomarkers and whether the associations are different (between sexes).

Methods

Data of 309 participants [92 with normal cognition, 148 with mild cognitive impairment (MCI), and 69 with AD dementia] from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were cross-sectionally evaluated with the multiple linear regression model and longitudinally with the multivariate linear mixed-effects model for the associations of CSF ApoE with AD biomarkers. Sex–ApoE interaction was used to estimate whether sex moderates the associations of CSF ApoE and AD biomarkers.

Results

Significant interactions between CSF ApoE and sex on AD biomarkers were observed [amyloid-β (Aβ): p = 0.0169 and phosphorylated-tau (p-tau): p = 0.0453]. In women, baseline CSF ApoE levels were significantly associated with baseline Aβ (p = 0.0135) and total-tau (t-tau) (p < 0.0001) as well as longitudinal changes of the biomarkers (Aβ: p = 0.0104; t-tau: p = 0.0110). In men, baseline CSF ApoE levels were only correlated with baseline p-tau (p < 0.0001) and t-tau (p < 0.0001) and did not aggravate AD biomarkers longitudinally.

Conclusion

The associations between CSF ApoE and AD biomarkers were sex-specific. Elevated CSF ApoE was associated with longitudinal changes of AD biomarkers in women, which indicates that CSF ApoE might be involved in the pathogenesis of AD pathology in a sex-specific way.

Keywords: Alzheimer’s disease, cerebrospinal fluid, Apolipoprotein E, sex, amyloid, tau, ADNI

Introduction

Alzheimer’s disease (AD) is the leading cause of dementia characterized by abnormal accumulation of β-amyloid (Aβ) (Hardy and Selkoe, 2002) and aggregation of hyperphosphorylated tau in the brain (Zempel and Mandelkow, 2014). A greater number of women have been diagnosed with AD compared with men according to the epidemiological indicators (Alzheimer’s Association, 2014), which can be partially explained by the sex-related differences in neural anatomy and function (Ingalhalikar et al., 2014; Ritchie et al., 2018). Addressing the sex-specific variation is crucial for the development of precise and effective therapeutics in AD.

It is well recognized that Apolipoprotein E (APOE) genotype is the strongest genetic risk factor for late-onset AD. Recent studies have found that the effect of APOE gene on AD is modified by sex (Altmann et al., 2014; Wang et al., 2019). Women between the ages of 65 and 75 with APOE ε3/ε4 have an increased risk of developing mild cognitive impairment (MCI) or AD compared with men (Neu et al., 2017), and the association between APOE ε4 and cerebrospinal fluid (CSF) tau level is stronger among women than men (Hohman et al., 2018). Animal studies also highlighted that impaired cognition and decreased presynaptic density were only observed in female APOE ε4 knockout mice (Rijpma et al., 2013; Pontifex et al., 2018). On the other hand, APOE ε2 was implicated to play a protective role in either men (Altmann et al., 2014; Zhao et al., 2015) or women (McFall et al., 2019).

Apolipoprotein E (ApoE), the APOE gene-encoded protein, has been suggested to be involved in a variety of pathogenic processes of AD. Several studies have reported that ApoE acts on Aβ deposition (Strittmatter et al., 1993; Bales et al., 1999; Tokuda et al., 2000; Baker-Nigh et al., 2016) and disrupts its clearance (Deane et al., 2008) in an isoform-dependent way. The lipidation status of ApoE has also been suggested to influence degradation of soluble Aβ peptides (Jiang et al., 2008). ApoE not only binds to soluble Aβ but also competes for its clearance pathways in the brain (Verghese et al., 2013). Similarly, ApoE was found to accelerate tau spreading (Wadhwani et al., 2019) and positively correlate with tau protein level (Lindh et al., 1997; van Harten et al., 2017). Moreover, ApoE was proposed to play a role in neurotoxicity (Mahley and Huang, 2012), mitochondrial dysfunction (Chen et al., 2011), and blood–brain barrier permeability (Teng et al., 2017; Main et al., 2018), which are all key mechanisms to AD pathogenesis. Clinical findings showed that high CSF ApoE concentration could predict the clinical progression of APOE ε4 carriers (van Harten et al., 2017), although no consensus has been reached for the association of CSF ApoE concentration with AD pathogenesis. Additionally, a recent study found that CSF ApoE mediated the positive association of APOE ε4 with tau without affecting the inverse relation between APOE ε4 and Aβ (Slot et al., 2019), indicating that CSF ApoE might be involved in AD pathology with mechanisms independent of those of APOE gene on AD pathology. However, whether the process is modified by sex has been mostly unexplored.

Interestingly, ApoE seems to be independently synthesized in the central nervous system and in the peripheral nervous system. It was found that most CSF ApoE was synthesized in the central nervous system, as it did not change to the donor’s phenotype after liver transplantation (Linton et al., 1991). Moreover, a study in mice revealed that plasma ApoE could not cross the blood–CSF barrier (Liu et al., 2012). It is known that the composition of CSF is similar to that of extracellular fluid of the brain tissue, and the CSF biomarkers are valid proxies for neuropathologic changes of AD (Jack et al., 2018). Therefore, we aim to explore whether there are sex-related associations of CSF ApoE and AD biomarkers using Alzheimer’s Disease Neuroimaging Initiative (ADNI) database.

Materials and Methods

Study Design and Data Sources

The study was designed to investigate whether there are sex-specific associations of CSF ApoE with well-validated AD biomarkers by means of cross-sectional and longitudinal analyses. Data were downloaded from the ADNI database1, which was launched in 2003 as a public–private partnership, led by principal investigator Michael W. Weiner, MD. It longitudinally collected detailed clinical, imaging, and laboratory data from more than 50 sites across the United States and Canada (the most recent information on the ADNI is available at http://www.adni-info.org). The filenames that contained the ApoE level are Biomarkers Consortium CSF Proteomics Project RBM Multiplex Data and Primer (Zip file) and Biomarkers Consortium Plasma Proteomics Project RBM Multiplex Data and Primer (Zip file) in the website https://ida.loni.usc.edu/pages/access/studyData.jsp?categoryId=11&subCategoryId=33. Institutional review boards of all participating institutions approved the ADNI, and written informed consent was obtained from all participants or authorized representatives. This study was approved by the ethics committee of our institution (IRB number: QYFYWZLL26124).

Participants

Our cohort consists of all cognitively normal (CN) controls and MCI and AD participants from ADNI-1. Detailed inclusion and exclusion criteria have been reported previously (Petersen et al., 2010). The inclusion criteria of this study are as follows: (1) available baseline CSF ApoE and AD biomarkers (Aβ, t-tau, and p-tau) measurements; (2) sufficient data of sociodemographic characteristics (age, sex, and education) and clinical evaluations [APOE ε4 genotype, baseline cognitive diagnosis, body mass index (BMI), history of cardiovascular disease, dyslipidemia, hypertension, and depression]. After excluding one participant without BMI information, 309 participants with sufficient data of baseline CSF ApoE and other information were included in the study. Besides, we included 356 participants with baseline plasma ApoE and sufficient data of sociodemographic and clinical information to evaluate the associations of baseline plasma ApoE with AD biomarkers.

Exposure Measures

The exposure measures include CSF ApoE and plasma ApoE. CSF ApoE was measured by the multiplex Human Discovery MAPTM panel on a Luminex 100 platform. Plasma was collected after an overnight fasting and plasma ApoE was measured by a 190-analyte multiplex immunoassay panel on the Luminex xMAP platform (see papers on methods and procedures available in http://www.adni-info.org).

Outcome Measures

Outcome measures include CSF Aβ, t-tau, and p-tau both at baseline and follow-ups. CSF was sampled through lumbar puncture and CSF Aβ, t-tau, and p-tau were measured by a multiplex xMAP platform with the INNOBIA AlzBio3 kit (Innogenetics, Ghent, Belgium) (Olsson et al., 2005). Participants have at least one follow-up measurement and the longest follow-up period is 5 years. A total of 870 measurements were included in the study. Longitudinal CSF data have been analyzed and described previously in detail (Toledo et al., 2013).

Covariates

Demographic information, APOE ε4 genotype, baseline cognitive diagnosis, and medical history were downloaded from the ADNI database. Other risk factors that might potentially affect the progress of AD were included in the present study, such as history of cardiovascular disease (i.e., myocardial infarction, intermittent claudication, angina, heart failure, and other evidence of coronary disease), dyslipidemia (i.e., hypercholesterolemia, low levels of high-density lipoprotein cholesterol, and hypertriglyceridemia), hypertension, BMI, and depression. Selection of the covariates was based on the previous studies (Livingston et al., 2017; Ferretti et al., 2018).

Statistical Analyses

Clinical and demographic variables of different groups were compared using the Kruskal–Wallis test for non-parametric variables and the Chi-square test for categorical variables. Spearman rank correlation was used for correlations between CSF ApoE and AD biomarkers.

Multiple linear regression model was performed to explore the cross-sectional associations of baseline CSF ApoE and AD biomarkers, with all outcome variables being standardized to z scores before entering into the model. Two predefined models were used with the following covariates (model 1: age, sex, APOE ε4 carrier status, education, and baseline cognitive diagnosis; model 2: model 1 plus cardiovascular disease, hypertension, BMI, dyslipidemia, and depression). Interaction between CSF ApoE and sex was further conducted in model 2 to evaluate the sex-specific associations of baseline CSF ApoE with AD biomarkers.

Multivariate linear mixed-effects model with random intercepts and slopes (time), termed time-by-ApoE interaction, was used to determine the associations of baseline CSF ApoE and longitudinal changes of AD biomarkers adjusted for the covariates in model 2. All outcome variables in the model were standardized to z scores to facilitate comparisons between modalities. Further analysis with a time-by-ApoE-by-sex interaction was included in the longitudinal analyses to evaluate whether CSF ApoE interacted with sex in association with longitudinal changes of AD biomarkers over the follow-up periods. All lower-order interactions of this three-way interaction term were included in the model.

A two-tailed p < 0.05 was considered statistically significant, except for the interaction analyses in the cross-sectional studies (p < 0.1), which aims to explore whether there was any potential interaction. R software, version 3.4.4 (R-project.org/), was used for all statistical analyses.

Results

Sample Characteristics

Baseline characteristics of the 309 participants are shown in Table 1. In brief, 92 CN controls (mean age, 75.70 ± 5.45; male, 50.0%), 148 MCI patients (mean age, 74.84 ± 7.23; male, 68.9%), and 69 AD patients (mean age, 74.94 ± 7.61; male, 56.5%) with available baseline CSF ApoE from ADNI-1 cohort were included. The level of CSF ApoE in men is higher than that in women (Table 1), and significant difference of CSF ApoE level among different APOE ε4 carrier status was found (Table 2). No significant differences of CSF ApoE were observed among the three study groups in the univariate analysis. There was also no significant difference in sex-stratified AD biomarkers (Table 1).

TABLE 1.

Demographic and clinical characteristics.

Women
 Men
 CN N = 92 MCI N = 148 AD N = 69 P1 P2
CN N = 46 MCI N = 46 AD N = 30 Total N = 122 CN N = 46 MCI N = 102 AD N = 39 Total N = 187
Age, years 76.26 ± 5.15 72.18 ± 6.78 73.76 ± 7.72 74.11 ± 7.54 75.15 ± 5.73 76.40 ± 7.14 75.85 ± 7.50 75.78 ± 6.88 75.70 ± 5.45 74.84 ± 7.23 74.94 ± 7.61 0.0309 0.8281
APOEε4 carriers 7 (17.39) 29 (63.04)a 22 (73.33)a 58 (47.54) 15 (34.78) 50 (49.02) 27 (69.23) 92 (49.20) 22 (23.91) 79 (53.38) 49 (71.01) 0.8662 <0.0001
BMI, kg/m2 26.26 ± 5.17 25.16 ± 4.26 24.15 ± 3.64 25.33 ± 4.21 26.74 ± 4.28 25.79 ± 3.59 26.03 ± 3.45 26.07 ± 3.74 26.50 ± 4.73 25.60 ± 3.80 25.21 ± 3.63 0.0652 0.1877
Educational level, years 14.74 ± 2.69 15.24 ± 2.88 14.3 ± 2.64 14.82 ± 2.80 16.52 ± 2.95 16.29 ± 2.92 15.82 ± 3.09 16.25 ± 2.96 15.63 ± 2.95 15.97 ± 2.94 15.16 ± 2.98 <0.0001 0.3382
CSF ApoE 7.20 ± 2.24 6.42 ± 1.74 5.96 ± 2.11 6.601 ± 48.33 7.41 ± 2.17 7.56 ± 2.40 6.91 (2.39) 7.39 ± 2.35 7.30 ± 2.20 7.21 ± 2.27 6.50 ± 2.31 0.0046 0.0571
CSF Aβ 212.80 ± 51.44 156.10 ± 44.37 141.50 ± 30.94 173.90 ± 59.42 203.20 ± 55.40 162.10 ± 51.37 141.40 ± 38.16 167.90 ± 54.28 160.32 ± 53.38 160.24 ± 49.23a 141.41 ± 34.96a,b 0.3074 <0.0001
CSF t-tau 69.93 ± 27.44 115.86 ± 52.23 137.8 ± 64.56 103.94 ± 64.05 67.76 ± 25.52 110.59 ± 52.79 110.25 ± 52.07 94.53 ± 49.74 68.85 ± 26.37 105.33 ± 52.92a 122.24 ± 59.01a,b 0.1197 <0.0001
CSF p-tau 23.44 ± 10.35 38.30 ± 15.43 42.38 ± 16.08 33.70 ± 19.27 26.13 ± 15.93 35.16 ± 15.51 40.13 ± 23.70 33.97 ± 18.19 24.79 ± 13.43 36.14 ± 15.50a 41.11 ± 20.63a,b 0.7774 <0.0001
Cardiovascular disease 8 (17.39) 11 (23.91) 5 (16.67) 24 (19.67) 23 (50.00) 33 (32.35) 19 (48.72) 75 (40.11) 31 (33.70) 44 (29.73) 24 (34.78) 0.0003 0.6987
Hypertension 25 (54.35) 18 (39.13) 16 (53.33) 59 (48.36) 20 (43.48) 53 (51.96) 18 (46.15) 91 (48.66) 45 (48.91) 71 (47.97) 34 (49.28) 1.0000 0.9806
Hyperlipoidemia 17 (36.96) 19 (41.30) 15 (50.00) 51 (41.80) 23 (50.00) 48 (47.06) 20 (51.28) 91 (48.66) 40 (43.48) 67 (45.27) 35 (50.72) 0.2864 0.6417
Depression 5 (10.87) 14 (30.43) 14 (46.67) 33 (27.05) 3 (6.52) 16 (15.69) 8 (20.51) 27 (14.44) 8 (8.70) 30 (2.02) 22 (31.88) 0.0095 0.0011
Mean follow-up, y 2.61 ± 1.69 1.98 ± 1.39 1.57 ± 0.86 2.16 ± 1.46 2.63 ± 1.57 2.31 ± 1.47 1.18 ± 0.51 2.11 ± 1.45 2.62 ± 1.62 2.21 ± 1.45 1.35 ± 0.70a,b 0.6999 <0.0001
Open in a new tab

BMI, body mass index; CSF, cerebrospinal fluid; ApoE, Apolipoprotein E; Aβ, amyloid-β; p-tau, phosphorylated tau; t-tau, total tau; MCI, mild cognitive impairment; CN, cognitively normal; AD, Alzheimer’s disease. Categorical data are shown as n (%) and continuous data are shown as mean ± SD. P1 value is comparison of the total participants in female and male groups. P2 value is comparison of the total participants in CN, MCI, and AD groups. aP < 0.01 compared to the total participants in CN. bP < 0.01 compared to the total participants in MCI.

TABLE 2.

Demographic and clinical characteristics of participants stratified by APOE ε4 carrier status.

APOE ε4 non-carriers N = 159 With one APOE ε4 allele N = 114 The APOE ε4/ε4 genotype N = 36 P
Age, years 75.76 ± 6.90 75.33 ± 6.45 71.61 ± 6.85 0.0040
Men 95 (59.75) 72 (63.16) 20 (55.56) 0.6897
BMI, kg/m2 26.31 ± 4.50 25.07 ± 3.42 25.69 ± 3.82 0.1102
Educational level, years 15.90 ± 3.01 15.61 ± 3.07 15.00 ± 2.20 0.1203
CSF ApoE 7.46 ± 2.29 6.76 ± 2.23 6.40 ± 2.08 <0.0001
CSF Aβ 199.00 ± 53.84 146.70 ± 34.26 117.90 ± 22.52 <0.0001
CSF t-tau 82.96 ± 48.17 112.50 ± 51.85 120.62 ± 50.64 <0.0001
CSF p-tau 28.24 ± 15.57 38.92 ± 15.98 42.74 ± 20.49 <0.0001
Cardiovascular disease 54 (33.96) 36 (31.58) 9 (25.00) 0.5768
Hypertension 85 (53.46) 49 (42.98) 16 (44.44) 0.2027
Hyperlipoidemia 62 (38.99) 57 (50.00) 23 (63.89) 0.0142
Depression 29 (18.24) 24 (21.05) 7 (19.45) 0.8454
Mean follow-up, years 2.31 ± 1.53 2.01 ± 1.34 1.81 ± 1.37 0.0624
Open in a new tab

BMI, body mass index; CSF, cerebrospinal fluid; ApoE, Apolipoprotein E; Aβ, amyloid-β; p-tau, phosphorylated tau; t-tau, total tau; MCI, mild cognitive impairment; CN, cognitively normal; AD, Alzheimer’s disease. Categorical data are shown as n (%) and continuous data are shown as mean ± SD.

During the 5-year-follow-up, 2 CN controls and 85 MCI patients progressed to AD, and the mean CSF ApoE is 7.03 μg/ml when these two groups are combined as a whole. The mean CSF ApoE is 7.37 μg/ml in study participants who did not progress to AD. No significant differences of CSF ApoE were observed between those who progressed to AD and those who did not (p = 0.3709).

Associations of CSF ApoE With CSF Biomarkers at Baseline

Cerebrospinal fluid ApoE levels were positively associated with t-tau [β (s.e.): 0.169 (0.021), p < 0.0001] and p-tau [β (s.e.): 0.098 (0.023), p < 0.0001], but not with Aβ [β (s.e.): 0.014 (0.020), p = 0.4742] for all the participants at baseline. Significant CSF ApoE-by-sex interactions with Aβ [β (s.e.): −0.101 (0.042), p = 0.0169] and p-tau [β (s.e.): 0.098 (0.049), p = 0.0453] were observed (Table 3). Further analysis stratified by sex showed that both women and men exhibited significant associations of CSF ApoE with t-tau, while the association of CSF ApoE with Aβ existed only in women, and the association of CSF ApoE with p-tau existed only in men (Table 4). The results were in line with those in Spearman’s correlation (Figure 1), which showed that CSF ApoE level was only positively associated with Aβ (r = 0.317, p < 0.001) in women, whereas the positive associations with t-tau (r = 0.473, p < 0.001) and p-tau (r = 0.340, p < 0.001) were only found in men.

TABLE 3.

Associations of CSF ApoE with CSF biomarkers at baseline.

Model 1
 Model 2
CSF ApoE
 CSF ApoE
 CSF ApoE × sex
β (s.e.) P β (s.e.) P β (s.e.) P
CSF Aβ 0.001 (0.002) 0.5400 0.014 (0.020) 0.4742 −0.101 (0.042) 0.0169*
CSF t-tau 0.176 (0.021) <0.0001* 0.169 (0.021) <0.0001* 0.029 (0.045) 0.5216
CSF p-tau 0.102 (0.023) <0.0001* 0.098 (0.023) <0.0001* 0.098 (0.049) 0.0453
Open in a new tab

Data are presented as standardized regression coefficients β and standard error (s.e.) with P values. *Signifies effect is significant when correcting for multiple comparisons (Bonferroni). Bold values mean statistically significant.

TABLE 4.

Stratified analysis of baseline data.

CSF Aβ
 CSF t-tau
 CSF p-tau
β (s.e.) P β (s.e.) P β (s.e.) P
Female 0.093 (0.037) 0.0135* 0.170 (0.037) <0.0001* 0.036 (0.039) 0.3576
Male -0.023 (0.024) 0.3509 0.181 (0.027) <0.0001* 0.122 (0.029) <0.0001*
Open in a new tab

Data are presented as standardized regression coefficients β and standard error (s.e.) with P values. The regression analysis was analyzed in model 2. *Signifies effect is significant when correcting for multiple comparisons (Bonferroni).

FIGURE 1.

FIGURE 1

Open in a new tab

Associations of baseline CSF ApoE concentration with AD biomarkers. Fit lines are shown for individual sex groups. (A) Association of CSF ApoE and amyloid-β (Aβ); (B) association of CSF ApoE and total tau (t-tau); (C) association of CSF ApoE and phosphorylated tau (p-tau). The coefficients r and P values are for Spearman rank correlation in each sex cohort.

Associations of Baseline CSF ApoE With Longitudinal Changes of CSF Biomarkers

Baseline CSF ApoE was not associated with longitudinal changes of CSF Aβ [β (s.e.): −0.002 (0.004), p = 0.6879], t-tau [β (s.e.): 0.005 (0.005), p = 0.2823], or p-tau [β (s.e.): 0.012 (0.009), p = 0.1796] in the multivariate linear mixed-effect model in all the participants (Table 5). However, a three-way interaction of ApoE-by-sex-by-time was found to be significantly associated with changes of Aβ [β (s.e.): 0.023 (0.009), p = 0.0096] and t-tau [β (s.e.): −0.027 (0.010), p = 0.0088]. Further analysis stratified by sex showed that ApoE was negatively associated with the longitudinal change of Aβ and positively associated with the change of t-tau in women (Table 6). No significant associations were found between baseline CSF ApoE and longitudinal changes of AD biomarkers in men. In women, baseline CSF ApoE was correlated with longitudinal changes of Aβ [β (s.e.): −0.018 (0.007), p = 0.0104] and t-tau [β (s.e.): 0.020 (0.007), p = 0.0110] during the following 5 years. As seen in Figure 2, participants with high CSF ApoE levels had a faster decrease of Aβ and increase of t-tau compared with those with low ApoE level during the following 5 years.

TABLE 5.

Associations of baseline CSF ApoE with longitudinal changes of CSF biomarkers.

Model 1
 Model 2
CSF ApoE
 CSF ApoE × time
 CSF ApoE × sex × time
β (s.e.) P β (s.e.) P β (s.e.) P
CSF Aβ −0.002 (0.004) 0.6880 −0.002 (0.004) 0.6879 0.023 (0.009) 0.0096*
CSF t-tau 0.005 (0.005) 0.2838 0.005 (0.005) 0.2823 −0.027 (0.010) 0.0088*
CSF p-tau 0.012 (0.009) 0.1780 0.012 (0.009) 0.1796 0.013 (0.019) 0.5060
Open in a new tab

Data are presented as standardized regression coefficients β and standard error (s.e.) with P values. *Signifies effect is significant when correcting for multiple comparisons (Bonferroni).

TABLE 6.

Stratified analysis of longitudinal data.

CSF Aβ
 CSF t-tau
 CSF p-tau
β (s.e.) P β (s.e.) P β (s.e.) P
Female −0.018 (0.007) 0.0104* 0.020 (0.007) 0.0110* 0.007 (0.016) 0.6736
Male 0.006 (0.005) 0.3131 −0.004 (0.007) 0.5481 0.020 (0.012) 0.0903
Open in a new tab

Data are presented as standardized regression coefficients β and standard error (s.e.) with P values. The regression analysis was analyzed in model 2. *Signifies effect is significant when correcting for multiple comparisons (Bonferroni).

FIGURE 2.

FIGURE 2

Open in a new tab

Associations of different CSF ApoE concentrations and longitudinal changes of CSF biomarkers. Longitudinal CSF Aβ (A), CSF t-tau (B), and CSF p-tau (C) change based on dichotomy of CSF ApoE level. For better visual display, the baseline values were held at the adjusted means for each sex group. High: ≥7.0 μg/ml, Low: <7.0 μg/ml. 7.0 μg/ml is the median for the baseline CSF ApoE. P value was the result of interaction between time and CSF ApoE level for linear mixed-effects models in each sex cohort.

Associations of CSF ApoE With CSF Sex Hormone-Binding Globulin at Baseline

The mean of CSF sex hormone-binding globulin (SHBG) was 0.14 nmol/L for CN control, 0.15 nmol/L for MCI patients, and 0.14 nmol/L for AD patients (p = 0.341). The Spearman correlation coefficient between baseline CSF SHBG and CSF ApoE was 0.278 (p = 6.977 × 10–7, Figure 3).

FIGURE 3.

FIGURE 3

Open in a new tab

Association between CSF ApoE concentration and sex hormone-binding globulin at baseline. The coefficients r and P values are for Spearman rank correlation in the whole cohort.

Associations of Baseline Plasma ApoE With CSF AD Biomarkers

At baseline, a total of 263 participants have both plasma ApoE and CSF ApoE measurements, the levels of which showed a mild correlation (r = 0.17, p = 0.005, Supplementary Figure 1) in the analysis. Besides, plasma ApoE levels of the 356 participants were positively associated with t-tau [β (s.e.): 0.003 (0.001), p = 0.0462] and had a significant interaction with sex on t-tau [β (s.e.): 0.006 (0.003), p = 0.0659] at baseline. Further analysis stratified by sex showed that the association of plasma ApoE with t-tau existed only in men [women: β (s.e.): 0.003 (0.002), p = 0.1426; men: β (s.e.): 0.007 (0.003), p = 0.0177]. However, baseline plasma ApoE was not associated with longitudinal changes of Aβ, t-tau, or p-tau in all participants. Similarly, no significant three-way interaction of time × plasma ApoE × sex was found (Supplementary Table 1).

Discussion

In this study, we observed significant sex-specific associations of CSF ApoE with AD biomarkers. In women, baseline CSF ApoE was significantly associated with both baseline CSF Aβ and t-tau as well as longitudinal changes of the biomarkers. However, the longitudinal associations were not observed in men, indicating that CSF ApoE could be considered as an early marker for AD in women.

Women have been found to have a higher risk of developing AD even after the prolonged life expectancy has been controlled (Li and Singh, 2014). Sex is a crucial variable in AD heterogeneity (Ferretti et al., 2018). Compared with men, women have a higher lifetime risk of developing AD (Seshadri et al., 1997) and are more likely to progress into severe clinical manifestations (Koran et al., 2017), have more extensive brain AD pathology (Corder et al., 2004; Barnes et al., 2005), and have faster brain atrophic rate measured by magnetic resonance imaging (Hua et al., 2010). Our results complement another mechanism of sex difference between CSF ApoE and major pathologies of AD, which might partly explain the greater disease burden of AD in women.

It is known that ApoE synergistically increases Aβ production (Sawmiller et al., 2019) and its deposit in the brain (Bales et al., 1999) and disrupts Aβ clearance process (Deane et al., 2008; Jiang et al., 2008; Verghese et al., 2013). In our current study, CSF ApoE was associated with increased baseline CSF Aβ and predicted its decline in the following 5 years in women. The result indicated that CSF ApoE might aggravate Aβ deposition in the brain (Bales et al., 1999) by acting as “pathological molecular chaperones” (Wisniewski and Frangione, 1992) to promote insolubility or neurotoxicity of CSF Aβ in the early stage of AD pathology (Hudry et al., 2019) and (or) by disrupting Aβ clearance process by competing for the same clearance pathways of soluble Aβ (Verghese et al., 2013). The level of CSF Aβ was abnormally low after the formation of insoluble amyloid plaque. In our findings, baseline CSF ApoE in women was associated with the longitudinal increase of t-tau without any association with p-tau. It is generally recognized that CSF t-tau is a biomarker for the intensity of neurodegeneration (Blennow and Zetterberg, 2018), and Aβ is the upstream of tau in the pathogenesis of AD by triggering tau from the normal state to toxic state (Bloom, 2014; Buckley et al., 2019). Therefore, besides the accumulation of upstream Aβ, CSF ApoE might promote neurodegeneration of AD via other mechanisms such as mitochondrial dysfunction (Yin et al., 2019), cytoskeletal alterations (Mahley and Huang, 2012), and inflammation (Shi and Holtzman, 2018). Our findings suggest that CSF ApoE can be an important promoter of the pathological process of AD in women.

In men, baseline CSF ApoE was only correlated with baseline tau pathology and was not associated with longitudinal AD biomarkers. A previous study has found that ApoE might affect tau pathogenesis independent of Aβ pathology (Shi et al., 2017). CSF ApoE was observed to increase after nerve injury (Aoki et al., 2003; Xu et al., 2006). These findings could partially explain the positive association of CSF ApoE with t-tau at baseline in both women and men. The results that CSF ApoE was not associated with the pathological deterioration of AD in men are in line with the previous findings using ADNI database in all participants (Toledo et al., 2014). However, after stratified by sex, we found that the association of ApoE and AD biomarkers was sex-specific and baseline CSF ApoE was only associated with the longitudinal changes of CSF Aβ and CSF t-tau in women.

We further explored the potential mechanism for the sex-specific association between CSF ApoE and AD neuropathology. Interestingly, we found that CSF SHBG, a major transport protein that modulates biologically active testosterone and estradiol, had a weak but significant positive correlation with CSF ApoE at baseline (r = 0.278, p = 6.977 × 10–7, Figure 3). Patients with AD were reported to have higher plasma SHBG levels, which may inactivate the functional testosterone and estradiol that are biologically neuroprotective (Xu et al., 2016). Prior work also demonstrated that the expression of APOE gene could be modulated by estrogen (Stone et al., 1997; Srivastava et al., 2008) and its receptors (Wang et al., 2006). Hence, we speculate that the sex-specific associations of CSF ApoE with AD biomarkers may be partially modulated by female sex hormones, which needs further exploration in the future. At the same time, we cannot ignore other potential mechanisms, such as that the half-life or production of ApoE in CSF is sex-specific.

The turnover rate of ApoE isoforms differs substantially in the central nervous system and in the peripheral nervous system (Wildsmith et al., 2012). In our study, we found a weak correlation between CSF ApoE and plasma ApoE. At baseline, plasma ApoE levels were positively associated with t-tau and had a significant interaction with sex on t-tau. However, baseline plasma ApoE was not associated with longitudinal changes of AD biomarkers, and there was no significant interaction of time × ApoE × sex. Hence, unlike CSF ApoE, plasma ApoE is not an early biomarker for AD cascade irrespective of sex. The result is in line with the findings in animal studies, which showed that ApoE in peripheral nervous system might function differently from ApoE in the central nervous system (Lane-Donovan et al., 2016), probably due to the fact that they cannot permeate the blood–brain barrier (Liu et al., 2012).

There are some limitations in this study. First, the small sample size and the potential sampling bias of ADNI (high proportion of men with AD) might limit the generalizability of these findings. Second, the missing longitudinal data might bias estimates of the longitudinal associations between baseline ApoE and AD biomarkers. Third, CSF ApoE with different ApoE isoforms (Yu et al., 2014), diverse origins (Brecht et al., 2004), and lipidation state (Jiang et al., 2008; Chernick et al., 2018) may have distinct function on neurodegeneration. In our study, we are unable to differentiate CSF ApoE isoforms, cellular origin, and lipidation state, all of which might be the potential factors affecting the association between CSF ApoE and AD biomarkers. Finally, although we have ruled out the confounding factors that could potentially affect AD progression, there are still possibilities that the covariates have causal relationships with CSF ApoE, which might reduce statistical power.

In summary, we found significant sex differences in the associations between CSF ApoE protein and AD biomarkers. In women, elevated CSF ApoE was associated with longitudinal changes of AD biomarkers, which might be an important promoter for the neurodegeneration of AD pathology. More work is needed to explore the potential mechanism underlying the role of ApoE in the pathogenesis of AD in women and how the association between sex hormones and ApoE influences AD pathology.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Ethics Statement

The study was approved by the Medical ethics committee of Affiliated Hospital of Qingdao University (IRB number: QYFYWZLL26124).

Author Contributions

J-TY, LT, and SC conceived this study, interpreted the data, and revised the manuscript. YL and WX determined the eligibility of the included studies and extracted the data independently. YL, J-HS, and X-HH conducted statistical analysis of the data and prepared all the figures. YL, J-QL, and X-HH drafted and modified the manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The authors’ disclosures are available online (www.j-alz.com/manuscript-disclosures/18-0971r2).

Funding. This study was supported by grants from the Natural Science Foundation of Shandong Province, China (Grant No. ZR2017MH098) and The Affiliated Hospital of Qingdao University.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2021.633576/full#supplementary-material

Click here for additional data file. (753.7KB, DOCX)

References

  1. Altmann A., Tian L., Henderson V. W., Greicius M. D. (2014). Sex modifies the APOE-related risk of developing Alzheimer disease. Ann. Neurol. 75 563–573. 10.1002/ana.24135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alzheimer’s Association (2014). 2014 Alzheimer’s disease facts and figures. Alzheimers Demen. 10:e47-92. [DOI] [PubMed] [Google Scholar]
  3. Aoki K., Uchihara T., Sanjo N., Nakamura A., Ikeda K., Tsuchiya K., et al. (2003). Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction. Stroke 34 875–880. 10.1161/01.str.0000064320.73388.c6 [DOI] [PubMed] [Google Scholar]
  4. Baker-Nigh A. T., Mawuenyega K. G., Bollinger J. G., Ovod V., Kasten T., Franklin E. E., et al. (2016). Human Central Nervous System (CNS) ApoE isoforms are increased by age, differentially altered by amyloidosis, and relative amounts reversed in the CNS compared with plasma. J. Biol. Chem. 291 27204–27218. 10.1074/jbc.M116.721779 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bales K. R., Verina T., Cummins D. J., Du Y., Dodel R. C., Saura J., et al. (1999). Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 96 15233–15238. 10.1073/pnas.96.26.15233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Barnes L. L., Wilson R. S., Bienias J. L., Schneider J. A., Evans D. A., Bennett D. A. (2005). Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch. Gen. Psychiatry 62 685–691. 10.1001/archpsyc.62.6.685 [DOI] [PubMed] [Google Scholar]
  7. Blennow K., Zetterberg H. (2018). Biomarkers for Alzheimer’s disease: current status and prospects for the future. J. Intern. Med. 284 643–663. 10.1111/joim.12816 [DOI] [PubMed] [Google Scholar]
  8. Bloom G. S. (2014). Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 71 505–508. 10.1001/jamaneurol.2013.5847 [DOI] [PubMed] [Google Scholar]
  9. Brecht W. J., Harris F. M., Chang S., Tesseur I., Yu G. Q., Xu Q., et al. (2004). Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 24 2527–2534. 10.1523/jneurosci.4315-03.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Buckley R. F., Mormino E. C., Chhatwal J., Schultz A. P., Rabin J. S., Rentz D. M., et al. (2019). Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiol. Aging 78 178–185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chen H. K., Ji Z. S., Dodson S. E., Miranda R. D., Rosenblum C. I., Reynolds I. J., et al. (2011). Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J. Biol. Chem. 286 5215–5221. 10.1074/jbc.M110.151084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chernick D., Ortiz-Valle S., Jeong A., Swaminathan S. K., Kandimalla K. K., Rebeck G. W., et al. (2018). High-density lipoprotein mimetic peptide 4F mitigates amyloid-beta-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia. J. Neurochem. 147 647–662. 10.1111/jnc.14554 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Corder E. H., Ghebremedhin E., Taylor M. G., Thal D. R., Ohm T. G., Braak H. (2004). The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann. N. Y. Acad. Sci. 1019 24–28. 10.1196/annals.1297.005 [DOI] [PubMed] [Google Scholar]
  14. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M. B., et al. (2008). apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118 4002–4013. 10.1172/jci36663 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ferretti M. T., Iulita M. F., Cavedo E., Chiesa P. A., Schumacher Dimech A., Santuccione Chadha A., et al. (2018). Sex differences in Alzheimer disease – the gateway to precision medicine. Nat. Rev. Neurol. 14 457–469. 10.1038/s41582-018-0032-9 [DOI] [PubMed] [Google Scholar]
  16. Hardy J., Selkoe D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297 353–356. [DOI] [PubMed] [Google Scholar]
  17. Hohman T. J., Dumitrescu L., Barnes L. L., Thambisetty M., Beecham G., Kunkle B., et al. (2018). Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol. 75 989–998. 10.1001/jamaneurol.2018.0821 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hua X., Hibar D. P., Lee S., Toga A. W., Jack C. R., Jr., Weiner M. W., et al. (2010). Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol. Aging 31 1463–1480. 10.1016/j.neurobiolaging.2010.04.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hudry E., Klickstein J., Cannavo C., Jackson R., Muzikansky A., Gandhi S., et al. (2019). Opposing roles of apolipoprotein E in aging and neurodegeneration. Life Sci. Alliance 2:e201900325. 10.26508/lsa.201900325 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ingalhalikar M., Smith A., Parker D., Satterthwaite T. D., Elliott M. A., Ruparel K., et al. (2014). Sex differences in the structural connectome of the human brain. Proc. Natl. Acad. Sci. U.S.A. 111 823–828. 10.1073/pnas.1316909110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Jack C. R., Bennett D. A., Blennow K., Carrillo M. C., Dunn B., Haeberlein S. B., et al. (2018). NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14 535–562. 10.1016/j.jalz.2018.02.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jiang Q., Lee C. Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., et al. (2008). ApoE promotes the proteolytic degradation of Abeta. Neuron 58 681–693. 10.1016/j.neuron.2008.04.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Koran M. E. I., Wagener M., Hohman T. J. (2017). Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav. 11 205–213. 10.1007/s11682-016-9523-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lane-Donovan C., Wong W. M., Durakoglugil M. S., Wasser C. R., Jiang S., Xian X., et al. (2016). Genetic restoration of plasma ApoE improves cognition and partially restores synaptic defects in ApoE-deficient mice. J. Neurosci. 36 10141–10150. 10.1523/jneurosci.1054-16.2016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Li R., Singh M. (2014). Sex differences in cognitive impairment and Alzheimer’s disease. Front. Neuroendocrinol. 35:385–403. 10.1016/j.yfrne.2014.01.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lindh M., Blomberg M., Jensen M., Basun H., Lannfelt L., Engvall B., et al. (1997). Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer’s disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci. Lett. 229 85–88. 10.1016/s0304-3940(97)00429-1 [DOI] [PubMed] [Google Scholar]
  27. Linton M. F., Gish R., Hubl S. T., Bütler E., Esquivel C., Bry W. I., et al. (1991). Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88 270–281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Liu M., Kuhel D. G., Shen L., Hui D. Y., Woods S. C. (2012). Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 303 R903–R908. 10.1152/ajpregu.00219.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Livingston G., Sommerlad A., Orgeta V., Costafreda S. G., Huntley J., Ames D., et al. (2017). Dementia prevention, intervention, and care. Lancet 390 2673–2734. 10.1016/S0140-6736(17)31363-6 [DOI] [PubMed] [Google Scholar]
  30. Mahley R. W., Huang Y. (2012). Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 76 871–885. 10.1016/j.neuron.2012.11.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Main B. S., Villapol S., Sloley S. S., Barton D. J., Parsadanian M., Agbaegbu C., et al. (2018). Apolipoprotein E4 impairs spontaneous blood brain barrier repair following traumatic brain injury. Mol. Neurodegener. 13:17. 10.1186/s13024-018-0249-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. McFall G. P., Bckman L., Dixon R. A. (2019). Nuances in Alzheimer’s genetic risk reveal differential predictions of non-demented memory aging trajectories: selective patterns by APOE genotype and sex. Curr. Alzheimer Res. 16 302–315. 10.2174/1567205016666190315094452 [DOI] [PubMed] [Google Scholar]
  33. Neu S. C., Pa J., Kukull W., Beekly D., Kuzma A., Gangadharan P., et al. (2017). Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol. 74 1178–1189. 10.1001/jamaneurol.2017.2188 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Olsson A., Vanderstichele H., Andreasen N., De Meyer G., Wallin A., Holmberg B., et al. (2005). Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51 336–345. [DOI] [PubMed] [Google Scholar]
  35. Petersen R. C., Aisen P. S., Beckett L. A., Donohue M. C., Gamst A. C., Harvey D. J., et al. (2010). Alzheimer’s disease neuroimaging initiative (ADNI): clinical characterization. Neurology 74 201–209. 10.1212/WNL.0b013e3181cb3e25 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Pontifex M., Vauzour D., Minihane A. M. (2018). The effect of APOE genotype on Alzheimer’s disease risk is influenced by sex and docosahexaenoic acid status. Neurobiol. Aging 69 209–220. 10.1016/j.neurobiolaging.2018.05.017 [DOI] [PubMed] [Google Scholar]
  37. Rijpma A., Jansen D., Arnoldussen I. A., Fang X. T., Wiesmann M., Mutsaers M. P., et al. (2013). Sex differences in presynaptic density and neurogenesis in middle-aged ApoE4 and ApoE knockout mice. J. Neurodegener. Dis. 2013:531326. 10.1155/2013/531326 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ritchie S. J., Cox S. R., Shen X., Lombardo M. V., Reus L. M., Alloza C., et al. (2018). Sex differences in the adult human brain: evidence from 5216 UK biobank participants. Cereb. Cortex 28 2959–2975. 10.1093/cercor/bhy109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Sawmiller D., Habib A., Hou H., Mori T., Fan A., Tian J., et al. (2019). A novel apolipoprotein E antagonist functionally blocks apolipoprotein E interaction with N-terminal amyloid precursor protein, reduces beta-amyloid-associated pathology, and improves cognition. Biol. Psychiatry 86 208–220. 10.1016/j.biopsych.2019.04.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Seshadri S., Wolf P. A., Beiser A., Au R., McNulty K., White R., et al. (1997). Lifetime risk of dementia and Alzheimer’s disease. The impact of mortality on risk estimates in the Framingham study. Neurology 49 1498–1504. [DOI] [PubMed] [Google Scholar]
  41. Shi Y., Holtzman D. M. (2018). Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 18 759–772. 10.1038/s41577-018-0051-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Shi Y., Yamada K., Liddelow S. A., Smith S. T., Zhao L., Luo W., et al. (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549 523–527. 10.1038/nature24016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Slot R. E. R., Kester M. I., Van Harten A. C., Jongbloed W., Bouwman F. H., Teunissen C. E., et al. (2019). ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Abeta42, levels in non-demented elderly. Neurobiol. Aging 79 101–109. 10.1016/j.neurobiolaging.2019.02.017 [DOI] [PubMed] [Google Scholar]
  44. Srivastava N., Averna M., Srivastava R. A. (2008). Dietary cholesterol and estrogen administration elevate brain apolipoprotein E in mice by different mechanisms. Indian J. Biochem. Biophys. 45 410–415. [PubMed] [Google Scholar]
  45. Stone D. J., Rozovsky I., Morgan T. E., Anderson C. P., Hajian H., Finch C. E. (1997). Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp. Neurol. 143 313–318. 10.1006/exnr.1996.6360 [DOI] [PubMed] [Google Scholar]
  46. Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L. M., Salvesen G. S., Pericak-Vance M., et al. (1993). Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 8098–8102. 10.1073/pnas.90.17.8098 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Teng Z., Guo Z., Zhong J., Cheng C., Huang Z., Wu Y., et al. (2017). ApoE influences the blood-brain barrier through the NF-kappaB/MMP-9 pathway after traumatic brain injury. Sci. Rep. 7:6649. 10.1038/s41598-017-06932-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B., et al. (2000). Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides. Biochem. J. 348(Pt 2) 359–365. [PMC free article] [PubMed] [Google Scholar]
  49. Toledo J. B., Da X., Weiner M. W., Wolk D. A., Xie S. X., Arnold S. E., et al. (2014). CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol. 127 621–632. 10.1007/s00401-013-1236-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Toledo J. B., Xie S. X., Trojanowski J. Q., Shaw L. M. (2013). Longitudinal change in CSF tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol. 126 659–670. 10.1007/s00401-013-1151-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. van Harten A. C., Jongbloed W., Teunissen C. E., Scheltens P., Veerhuis R., van der Flier W. M. (2017). CSF ApoE predicts clinical progression in nondemented APOEepsilon4 carriers. Neurobiol. Aging 57 186–194. 10.1016/j.neurobiolaging.2017.04.002 [DOI] [PubMed] [Google Scholar]
  52. Verghese P. B., Castellano J. M., Garai K., Wang Y., Jiang H., Shah A., et al. (2013). ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc. Natl. Acad. Sci. U.S.A. 110 E1807–E1816. 10.1073/pnas.1220484110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Wadhwani A. R., Affaneh A., Van Gulden S., Kessler J. A. (2019). Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in Alzheimer disease. Ann. Neurol. 85 726–739. 10.1002/ana.25455 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Wang J. M., Irwin R. W., Brinton R. D. (2006). Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 103 16983–16988. 10.1073/pnas.0608128103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Wang X., Zhou W., Ye T., Lin X., Zhang J. (2019). Sex difference in the association of APOE4 with memory decline in mild cognitive impairment. J. Alzheimers Dis. 69 1161–1169. 10.3233/jad-181234 [DOI] [PubMed] [Google Scholar]
  56. Wildsmith K. R., Basak J. M., Patterson B. W., Pyatkivskyy Y., Kim J., Yarasheski K. E., et al. (2012). In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS One 7:e38013. 10.1371/journal.pone.0038013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Wisniewski T., Frangione B. (1992). Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135 235–238. 10.1016/0304-3940(92)90444-c [DOI] [PubMed] [Google Scholar]
  58. Xu J., Xia L. L., Song N., Chen S. D., Wang G. (2016). Testosterone, estradiol, and sex hormone-binding globulin in Alzheimer’s disease: a meta-analysis. Curr. Alzheimer Res. 13 215–222. 10.2174/1567205013666151218145752 [DOI] [PubMed] [Google Scholar]
  59. Xu Q., Bernardo A., Walker D., Kanegawa T., Mahley R. W., Huang Y. (2006). Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 26 4985–4994. 10.1523/jneurosci.5476-05.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Yin J., Nielsen M., Carcione T., Li S., Shi J. (2019). Apolipoprotein E regulates mitochondrial function through the PGC-1α-sirtuin 3 pathway. Aging 11 11148–11156. 10.18632/aging.102516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Yu J. T., Tan L., Hardy J. (2014). Apolipoprotein E in Alzheimer’s disease: an update. Annu. Rev. Neurosci. 37 79–100. 10.1146/annurev-neuro-071013-014300 [DOI] [PubMed] [Google Scholar]
  62. Zempel H., Mandelkow E. (2014). Lost after translation: missorting of tau protein and consequences for Alzheimer disease. Trends Neurosci. 37 721–732. 10.1016/j.tins.2014.08.004 [DOI] [PubMed] [Google Scholar]
  63. Zhao L., Woody S. K., Chhibber A. (2015). Estrogen receptor beta in Alzheimer’s disease: from mechanisms to therapeutics. Ageing Res. Rev. 24(Pt B) 178–190. 10.1016/j.arr.2015.08.001 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (753.7KB, DOCX)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Articles from Frontiers in Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES